HOME >> BIOLOGY >> NEWS
Einstein researchers find potential new drugs for tuberculosis

Researchers at the Albert Einstein College of Medicine of Yeshiva University have synthesized chemicals that are up to 10 times more effective than isoniazid, the leading anti-tuberculosis drug. The finding could lead to badly needed new drugs for combating tuberculosis bacteria, which each year kill an estimated 2.4 million people worldwide. The study appears in the March issue of Chemistry & Biology.

One of the chemicals, 2-HA, was found to be four times more lethal than isoniazid against the bacteria, while the other, 2-OA, proved 10 times more effective. These chemically similar drugs don't appear to harm higher organisms, so they could probably be used against TB bacteria without risk to patients.

"Drug-resistant mycobacterium tuberculosis is a worldwide problem, particularly in people with weakened immune systems such as those infected with HIV," notes senior author Dr. William Jacobs, a Howard Hughes Medical Institute investigator at Einstein, as well as professor of microbiology & immunology and molecular genetics. "So we urgently need to develop new and more effective antituberculosis drugs."

Isoniazid, today's first-line anti-TB drug, stops TB bacteria from forming mycolic acid, a key building block for their cell walls. It does the job by targeting an enzyme called InhA. Trying to improve upon isoniazid, the Einstein researchers synthesized more than a dozen chemical "decoys" for InhA to latch onto, to prevent the enzyme from catalyzing its normal cell-wall-building reaction. Two of these decoy chemicals, 2-HA and 2-OA, proved much more potent than isoniazid at killing the bacteria--but not in the way the researchers expected.

"We were surprised to find that 2-HA and 2-OA were actually being metabolized in mycobacteria into two different drugs, each of which inhibits a different biochemical pathway," says Dr. Catherine Vilchze, a study co-author in Dr. Jacobs' laboratory. "The pathways that they block - fatty acid and my
'"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
24-Mar-2006


Page: 1 2

Related biology news :

1. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
2. Einstein researchers prototype vaccine could provide improved protection against tuberculosis
3. Einstein researchers discover radiation-eating fungi
4. Einsteins Dr. Vern Schramm elected to the National Academy of Sciences
5. Einstein researchers discover how a key dietary vitamin is absorbed
6. NCI funds Einstein and U. Albany NanoCollege to make worlds smallest cancer detection device
7. Team at CNSE and Einstein receive grant to develop worlds smallest cancer detection device
8. Einstein researchers demonstrate a novel approach to treating AIDS
9. Einsteins Dr. E. Richard Stanley receives 2006 E. Donnall Thomas Prize
10. Einstein researchers find key to unlocking worlds deadliest malaria parasite
11. Findings by Einstein scientists reveal possible strategy against obesity, diabetes and infertility

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company ... Drug Administration (FDA) has approved the company’s Investigational New Drug (IND) application for ... Approval of this IND allows Sentien to initiate a Phase 1/2 study with ...
(Date:8/12/2020)... Mich. (PRWEB) , ... August 11, 2020 , ... ... R&D subsidiary based in Princeton, NJ, have entered into license agreements with Housey ... and development. Both Roche and J&J have annual Research and Development spending ...
(Date:8/5/2020)... ... 05, 2020 , ... Regenative Labs has received approval from the Centers for ... them the first Wharton’s jelly allografts to be assigned a Q code and be ... the first Wharton’s jelly allograft product to be recognized as a 361 HCT/P by ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... 2020 , ... Bode Technology, a leading provider ... through its COVID-19 testing service, Bode-CARES . Bode-CARES combines high-volume clinical testing ... provides a turnkey solution that includes a comprehensive collection and virus-management program for ...
(Date:7/10/2020)... ... July 09, 2020 , ... Sentien Biotechnologies, ... the hiring of Allen R. Nissenson, M.D., F.A.C.P., as its Chief Medical Officer. ... of Sentien’s lead product, SBI-101. Dr. Nissenson serves as an Emeritus Professor ...
(Date:7/1/2020)... (PRWEB) , ... June 29, 2020 , ... ... year to date growth of 40% in 2020, despite many obstacles created as ... MedShift aims to increase revenue for its partnered medical practices and medical manufacturers ...
(Date:6/28/2020)... ... 2020 , ... The Indoor Lab, a leading provider of sensor solutions for ... types to ensure cleanliness, distancing and occupancy with its patent pending WipeAway™ technology using ... will provide a health performance index system that scores all aspects of compliance similar ...
Breaking Biology Technology:
Cached News: